Solid Biosciences Inc. SLDB
7.60 USD +0.43 (+6.00%)
At closeNov 11, 2026, 4:00 PM EST
7.60 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
7.18 Day range 7.86
4.16 52-week range 11.45
- YTD
- +34.75%
- 1 year
- +67.77%
News
benzinga.com Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy The collaboration will evaluate combining the circVec generation 5 construct into POLARIS-101TM to address major unmet medical needs in genetic heart diseaseSolid Biosciences´ proprietary,…
globenewswire.com Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
globenewswire.com Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
benzinga.com Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia - Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia -- SGT-212 is a…
benzinga.com UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20 UBS analyst Joon Lee initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $20.